雷帕鸣治疗肾移植的效果如何？

Rapamin (sirolimus tablets, sirolimus) is suitable for patients receiving kidney transplants to prevent organ rejection. It is recommended that Rapamune preparations be used in combination with cyclosporine and corticosteroids. Rapamin inhibits the activation and proliferation of T lymphocytes stimulated by antigens and cytokines (interleukins IL-2, IL-4 and IL-15). It also inhibits the production of antibodies. In cells, it binds to the immunophilin, FK-binding protein-12 (FKBP-12), to generate the FKBP-12 immunosuppressive complex. This complex binds to the mammalian sirolimus BA molecule (mTOR) and inhibits its activity, thereby inhibiting the progression from G1 phase to S phase in the cell cycle.

How effective is Rapamin in the treatment of kidney transplantation?

Clinical trials explore the clinical efficacy and safety of sirolimus (sirolimus) in kidney transplantation. A total of 23 kidney transplant patients were selected in the trial and given triple immunosuppressive therapy of rapamycin (sirolimus) combined with cyclosporine and glucocorticoids. Start taking sirolimus within 48 hours after transplantation, with a loading dose of 6 mg and a maintenance dose of 2 mg.

The results showed that 22 patients completed 6 to 12 months of follow-up. The incidence rates of acute rejection (AR) at 6 and 12 months were 13.6% (3 cases/22 cases) and 15.8% (3 cases/19 cases) respectively. AR patients were reversed after methylprednisolone pulse treatment and continued to be followed up for more than half a year. No recurrence of AR was found. The main adverse reaction was hyperlipidemia (56.5%, 13 cases/23 cases). After reducing the dosage of sirolimus or applying lipid-lowering drugs, the patient's blood lipids dropped to normal or slightly higher than normal levels. Graft vascular disease and cardiovascular complications have not increased since follow-up.